# Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma

> **NCT01924624** · NA · UNKNOWN · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 140 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Recurrence

## Interventions

- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT01924624
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-07
- **Primary completion:** 2015-08
- **Final completion:** 2019-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2013-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01924624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01924624, "Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01924624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*